viewCannPal Animal Therapeutics Ltd
80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost price.
() non-executive chairman Geoff Starr has purchased 80,000 shares in the company via on-market trades.
The $10,193 parcel is Starr’s first purchase of company shares and his first step to aligning himself with shareholders.
READ: CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase
CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.
The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.
In the recent December quarterly report chairman Geoff Starr said: “I’m extremely happy with the progress that CannPal has made in the December quarter, and particularly the company’s progress with our nutraceutical program, while maintaining focus on our lead pharmaceutical.
“Our strategy has been to remain focused and diligent in the development of compliant animal health products and that work is beginning to pay off as we’re getting closer towards getting CannPal in a position to explore commercialisation opportunities in 2019.
“I’m looking forward to the team continuing with the same momentum throughout the new-year.”
ASX:CP1
Market: ASX
Market Cap: $13.5 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market
CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...
on 06/24/2018
2 min read
Prev article
5 min read
